Clinical Trials Logo

Clinical Trial Summary

This study examines how gut microbiome can affect cancer therapy in cancer patients undergoing cancer therapy or stem cell transplant. The human microbiome affects the way some cancer drugs are metabolized in the human body. Information from this study may help doctors improve the way cancer treatment is delivered, and increase its effectiveness and success.


Clinical Trial Description

PRIMARY OBJECTIVE: I. To correlate gut microbiome with specific cancer diagnoses and the clinical response (efficacy), and adverse effects of cancer therapy (single or multiple) and stem cell transplant. OUTLINE: Patients undergo collection of blood and stool samples and have their medical records reviewed. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05112614
Study type Observational
Source Mayo Clinic
Contact
Status Recruiting
Phase
Start date September 11, 2019
Completion date October 1, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT05106374 - Risk of Chemotherapy Toxicity in Older Patients With Blood Cancer or Non-small Cell Lung Cancer
Recruiting NCT04060849 - Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY Phase 1
Recruiting NCT04666025 - SARS-CoV-2 Donor-Recipient Immunity Transfer
Withdrawn NCT04127721 - Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation Phase 2
Recruiting NCT03712878 - 2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies Phase 2
Recruiting NCT04314401 - National Cancer Institute "Cancer Moonshot Biobank"
Recruiting NCT04983901 - Imipenem, Cilastatin Sodium, and Relebactam Monohydrate for the Treatment of Cancer Patients With Febrile Neutropenia Phase 2
Recruiting NCT04320888 - Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial Phase 2
Recruiting NCT04188912 - Close Assessment and Testing for Chronic Graft Versus Host Disease, CATCH Study
Recruiting NCT04592250 - Financial Toxicity in Cancer Patients
Recruiting NCT04296305 - Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain Phase 4
Recruiting NCT04060277 - Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation Phase 2
Active, not recruiting NCT02464696 - Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure N/A
Not yet recruiting NCT04874194 - Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1 Phase 1/Phase 2
Recruiting NCT04820894 - Perception of Cure Among Patients With Metastatic Cancer
Active, not recruiting NCT01664910 - CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT04089358 - Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors, the StepByStep Study Phase 3
Recruiting NCT05031897 - Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant Phase 2
Recruiting NCT04188418 - Fentanyl Buccal Tablet or Morphine for Exertional Dyspnea in Cancer Patients Phase 3